Abstract
We aimed to investigate the effectivity of the 0.0625mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625mg dose of intravitreal bevacizumab (IVB) injection. The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n=46) (full dose of bevacizumab-0.625mg/0.025ml) and group L (n=45) (low dose (one tenth) of bevacizumab-0.0625mg/0.025ml). Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168±65 and 97±29days, respectively (p<0.001). Disappearance of plus sign is observed earlier in group F (2.45±1.7 vs 3.66±2.46days, respectively, p=0.03). The low dose (0.0625mg) of IVB treatment was effective as full (0.625mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
